PREMIUM: Getting under the skin of exposure – a case study in pharma

     

We recently spoke to the CEO of a young pharma ‘big data’ business.  We found the proposition interesting as an example of how commercial / industrial insurers can improve their underwriting decision-making from the better use of data – right now.

This is a premium blog post emailed to our research and consulting clients. If you are interested in hearing about our competitor insights product, premium InsurTech research or other subscription services, please get in touch.

Get in touch to see how we can help

Email

info@oxbowpartners.com

Contact us

Stay informed

Select which Oxbow Partners insights to receive directly to your inbox

About the author

Chris Sandilands, ACII is a Partner at Oxbow Partners. Chris advises (re)insurers and brokers on a range of strategy topics and M&A. Chris started his career as a D&O underwriter at Munich Re, before joining Oliver Wyman, the consulting firm. You can reach him at csandilands@oxbowpartners.com.

Stay informed

Get insights and market news from Oxbow Partners straight to your inbox
Holler Box